ES2155219T3 - Compuestos nucleotidos de fosfonato. - Google Patents

Compuestos nucleotidos de fosfonato.

Info

Publication number
ES2155219T3
ES2155219T3 ES97100652T ES97100652T ES2155219T3 ES 2155219 T3 ES2155219 T3 ES 2155219T3 ES 97100652 T ES97100652 T ES 97100652T ES 97100652 T ES97100652 T ES 97100652T ES 2155219 T3 ES2155219 T3 ES 2155219T3
Authority
ES
Spain
Prior art keywords
halogen
alkyl
substituted
phosphonate
nucleotid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97100652T
Other languages
English (en)
Inventor
Masaru Ubasawa
Kouichi Sekiya
Hideaki Takashima
Naoko Ueda
Satoshi Yuasa
Naohiro Kamiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Application granted granted Critical
Publication of ES2155219T3 publication Critical patent/ES2155219T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

UN COMPUESTO DE NUCLEOTIDO DE FOSFONATO QUE TIENE ACTIVIDAD ANTIVIRAL ES UTIL PARA UNA DISPONIBILIDAD ORAL Y AGENTE ANTIVIRAL ALTAMENTE SEGURO, EL CUAL ESTA REPRESENTADO POR LA SIGUIENTE FORMULA (I): EN DONDE R{SUP,1} REPRESENTA HIDROGENO, ALCOXI C{SUB,1}-C{SUB,6}, UN ALCOXI C{SUB,1}-C{SUB,4} SUSTITUIDO POR HALOGENO, HALOGENO, AMINO, O NITRO; R{SUP,2} Y R{SUP,3} REPRESENTAN INDEPENDIENTEMENTE HIDROGENO, UN ALQUILO C{SUB,1}-C{SUB,22}, UN ACILOXIMETILO, UN ACILTIOETILO, O UN ETILO SUSTITUIDO POR HALOGENO; R{SUP,4} REPRESENTA HIDROGENO, UN ALQUILO C{SUB,1}C{SUB,4}, UN HIDROXIALQUILO C{SUB,1}-C{SUB,4}, O UN ALQUILO C{SUB,1}-C{SUB,4} SUSTITUIDO POR HALOGENO; Y X REPRESENTA.
ES97100652T 1996-01-18 1997-01-17 Compuestos nucleotidos de fosfonato. Expired - Lifetime ES2155219T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP648096 1996-01-18

Publications (1)

Publication Number Publication Date
ES2155219T3 true ES2155219T3 (es) 2001-05-01

Family

ID=11639647

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97100652T Expired - Lifetime ES2155219T3 (es) 1996-01-18 1997-01-17 Compuestos nucleotidos de fosfonato.

Country Status (12)

Country Link
US (1) US5840716A (es)
EP (1) EP0785208B1 (es)
KR (1) KR100366727B1 (es)
CN (2) CN1088712C (es)
AT (1) ATE199907T1 (es)
CA (1) CA2195262C (es)
DE (1) DE69704286T2 (es)
DK (1) DK0785208T3 (es)
ES (1) ES2155219T3 (es)
GR (1) GR3035776T3 (es)
PT (1) PT785208E (es)
TW (1) TW369536B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426904T2 (de) * 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
KR20000029952A (ko) 1996-08-13 2000-05-25 미우라 아끼라 포스포네이트뉴클레오티드화합물
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
WO2001064693A1 (fr) * 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Compose de nucleotide de phosphonate
JP2005508924A (ja) * 2001-08-30 2005-04-07 三菱ウェルファーマ株式会社 抗ウイルス剤
US20040023928A1 (en) * 2001-10-31 2004-02-05 Colacino Joseph Matthew Phosphonate nucleotide and thiadiazole compounds for the treatment of smallpox
JP2005511749A (ja) * 2001-12-07 2005-04-28 三菱ウェルファーマ株式会社 Ｂ型肝炎ウィルス感染症を治療するためのホスホネートヌクレオチド類似体の使用
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
WO2004024743A1 (ja) * 2002-09-13 2004-03-25 Mitsubishi Pharma Corporation ２−アミノ−６−（４−メトキシフェニルチオ）−９−[２−（ホスホノメトキシ）エチル]プリン ビス（２，２，２−トリフルオロエチル）エステルの結晶
AU2003280798A1 (en) * 2002-11-15 2004-06-15 Mitsubishi Pharma Corporation Process for producing 2-(bis(2,2,2-trifluoroethyl)phosphonylmethoxy)ethyl halide
AU2003280799A1 (en) * 2002-11-15 2004-06-15 Mitsubishi Pharma Corporation Medicinal composition
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
CN100475825C (zh) * 2004-03-19 2009-04-08 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物
US8101745B2 (en) * 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
CN1827627B (zh) * 2005-03-04 2011-05-11 北京美倍他药物研究有限公司 新的无环核苷膦酸及其酯衍生物及其医药用途
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
EP2161023A3 (en) 2007-04-13 2010-12-29 Southern Research Institute Anti-angiogenic agents and methods of use.
CN101293899B (zh) * 2007-04-28 2011-12-07 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
CN105055432A (zh) * 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011017253A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CN102093422B (zh) * 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CN102286026B (zh) * 2010-06-18 2014-07-02 中国人民解放军军事医学科学院毒物药物研究所 无环核苷酸类似物的盐及其晶型和药物组合物
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020932D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
EP0618214A1 (en) * 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
DE69426904T2 (de) * 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate

Also Published As

Publication number Publication date
KR100366727B1 (ko) 2003-03-15
TW369536B (en) 1999-09-11
ATE199907T1 (de) 2001-04-15
EP0785208A1 (en) 1997-07-23
CA2195262A1 (en) 1997-07-19
DK0785208T3 (da) 2001-04-23
GR3035776T3 (en) 2001-07-31
CN1216060C (zh) 2005-08-24
EP0785208B1 (en) 2001-03-21
KR970059181A (ko) 1997-08-12
DE69704286T2 (de) 2001-10-25
PT785208E (pt) 2001-06-29
CN1164534A (zh) 1997-11-12
US5840716A (en) 1998-11-24
CN1398864A (zh) 2003-02-26
CA2195262C (en) 2005-08-09
DE69704286D1 (de) 2001-04-26
CN1088712C (zh) 2002-08-07

Similar Documents

Publication Publication Date Title
DE69704286D1 (de) Phosphonat-Nukleotid-Verbindungen
AP2000001803A0 (en) Chemical compounds
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
HU9502512D0 (en) Anthranilic acid derivative
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
MXPA02004440A (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii.
ES2142773A1 (es) Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
TW427979B (en) A condensed piperidine compound
DK1031556T3 (da) 2-phenoxyanilinderivater
MX9701949A (es) Derivados de distamicina substituidos con bis-(2-haloetil) aminofenilo como agentes antitumorales y antivirales.
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
AU7810787A (en) 6-{2-(3-phenoxy-2-hydroxy-propylamino)-propyl-amino}-5- methyl-pyrizine-3-one derivatives useful as antihyper- tensive agents
DE69612967D1 (en) Optisch aktive thiazolidinonderivate
TW356471B (en) Novel carbocyclic nucleoside agents useful as selective inhibitor of proinflammatory cytokines
DK1163258T3 (da) Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
DE69516849D1 (de) Pyridazinon-derivate
NO972905L (no) Tienoksasinon-derivater anvendelige som antivirusmidler
CA2419463A1 (en) Primary intermediates for oxidative coloration of hair
AU5660598A (en) Use of aminoisothiazoles as microbicides
EG24798A (en) Pyrazole compound.
CO4940468A1 (es) Nuevos derivados de naftilpiperacina
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents
BR9305092A (pt) Processo para a preparação de derivados de 5-pirazolmercáptan, composto ditiocarbazato de etilideno, processo para a preparação de derivados do mesmo
WO1999011621A3 (en) Thiourea for increasing hdl-cholesterol levels, which are useful as anti-atherosclerotic agents
ES2067388A1 (es) Procedimiento para la produccion de derivados de piroglutamato de configuracion 2,4-cis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 785208

Country of ref document: ES